P452: Impact of implementing a rapid access clinic in a high-volume inflammatory bowel disease centre: accessibility, resource utilisation and outcomes
ECCO '19 Copenhagen
2019
P453: Golimumab in real-world practice in patients with ulcerative colitis: 2-year interim results from a non-interventional trial in Germany
ECCO '19 Copenhagen
2019
P454: Prediction of endoscopic activity in patients with Crohn’s disease: systematic review and external validation of published prediction models
ECCO '19 Copenhagen
2019
P455: Evaluation of the optic nerve function in patients with ulcerative colitis and Crohn’s disease
ECCO '19 Copenhagen
2019
P456: Quality of life is associated with wearable-based physical activity in patients with inflammatory bowel disease: a prospective, observational study
ECCO '19 Copenhagen
2019
P457: Influence of concomitant immunomodulators during maintenance therapy with Adalimumab in inflammatory bowel disease: looking for the ideal patient to use monotherapy
ECCO '19 Copenhagen
2019
P458: Effect of cognitive behavioural therapy on clinical disease course in adolescents and young adults with inflammatory bowel disease and subclinical anxiety and/or depression: results of a randomised trial
ECCO '19 Copenhagen
2019
P459: Vedolizumab for the treatment of chronic pouchitis: the Edinburgh experience
ECCO '19 Copenhagen
2019
P460: Efficacy of ustekinumab in patients with anti-TNF refractory Crohn’s disease: data from a real-world study in Brazil
ECCO '19 Copenhagen
2019
P461: Endoscopic features for loss of response in patients with Crohn’s disease who were treated with infliximab by top-down strategy
ECCO '19 Copenhagen
2019
P463: Factors to determine prognosis of intestinal cancer associated with Crohn’s disease
ECCO '19 Copenhagen
2019
P464: Study of the usual aetiologies of methotrexate and azathioprine discontinuation in inflammatory bowel disease
ECCO '19 Copenhagen
2019
P465: UC trial designed more than 5 years ago in the light of the EMA guideline on the development of new medicinal products for the treatment of ulcerative colitis
ECCO '19 Copenhagen
2019
P466: Tofacitinib for the treatment of ulcerative colitis: Up to 5.4 years of safety data from global clinical trials
ECCO '19 Copenhagen
2019
P467: Circulating CD8 α4β7+ and CD8b7+ memory T cells as early biomarkers of clinical response to vedolizumab in ulcerative colitis
ECCO '19 Copenhagen
2019
P468: Long-term function after transanal vs. transabdominal ileal pouch-anal anastomosis for ulcerative colitis: a multi-centre cohort study
ECCO '19 Copenhagen
2019
P469: Effectiveness of dose optimisation by pre-genotyping NUDT 15 R139C on reducing thiopurine-induced leucopoenia in Chinese patients with Crohn’s disease: a randomised controlled trial
ECCO '19 Copenhagen
2019